Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Anxiety Disorders
Copyright © 2020. Published by Elsevier Inc..
Anxiety disorders are among the most common psychiatric disorders in children and adolescents. As reviewed in this guideline, both cognitive-behavioral therapy (CBT) and selective serotonin reuptake inhibitor (SSRI) medication have considerable empirical support as safe and effective short-term treatments for anxiety in children and adolescents. Serotonin norepinephrine reuptake inhibitor (SNRI) medication has some empirical support as an additional treatment option. In the context of a protracted severe shortage of child and adolescent-trained behavioral health specialists, research demonstrating convenient, efficient, cost-effective, and user-friendly delivery mechanisms for safe and effective treatments for child and adolescent anxiety disorders is an urgent priority. The comparative effectiveness of anxiety treatments, delineation of mediators and moderators of effective anxiety treatments, long-term effects of SSRI and SNRI use in children and adolescents, and additional evaluation of the degree of suicide risk associated with SSRIs and SNRIs remain other key research needs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Journal of the American Academy of Child and Adolescent Psychiatry - 59(2020), 10 vom: 01. Okt., Seite 1107-1124 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Walter, Heather J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.03.2021 Date Revised 16.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaac.2020.05.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310216583 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310216583 | ||
| 003 | DE-627 | ||
| 005 | 20231225135620.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaac.2020.05.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1034.xml |
| 035 | |a (DE-627)NLM310216583 | ||
| 035 | |a (NLM)32439401 | ||
| 035 | |a (PII)S0890-8567(20)30280-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Walter, Heather J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Anxiety Disorders |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2021 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020. Published by Elsevier Inc. | ||
| 520 | |a Anxiety disorders are among the most common psychiatric disorders in children and adolescents. As reviewed in this guideline, both cognitive-behavioral therapy (CBT) and selective serotonin reuptake inhibitor (SSRI) medication have considerable empirical support as safe and effective short-term treatments for anxiety in children and adolescents. Serotonin norepinephrine reuptake inhibitor (SNRI) medication has some empirical support as an additional treatment option. In the context of a protracted severe shortage of child and adolescent-trained behavioral health specialists, research demonstrating convenient, efficient, cost-effective, and user-friendly delivery mechanisms for safe and effective treatments for child and adolescent anxiety disorders is an urgent priority. The comparative effectiveness of anxiety treatments, delineation of mediators and moderators of effective anxiety treatments, long-term effects of SSRI and SNRI use in children and adolescents, and additional evaluation of the degree of suicide risk associated with SSRIs and SNRIs remain other key research needs | ||
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anxiety | |
| 650 | 4 | |a assessment | |
| 650 | 4 | |a child psychiatry | |
| 650 | 4 | |a clinical practice guideline | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a Serotonin Uptake Inhibitors |2 NLM | |
| 650 | 7 | |a Serotonin and Noradrenaline Reuptake Inhibitors |2 NLM | |
| 650 | 7 | |a Serotonin |2 NLM | |
| 650 | 7 | |a 333DO1RDJY |2 NLM | |
| 700 | 1 | |a Bukstein, Oscar G |e verfasserin |4 aut | |
| 700 | 1 | |a Abright, A Reese |e verfasserin |4 aut | |
| 700 | 1 | |a Keable, Helene |e verfasserin |4 aut | |
| 700 | 1 | |a Ramtekkar, Ujjwal |e verfasserin |4 aut | |
| 700 | 1 | |a Ripperger-Suhler, Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Rockhill, Carol |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Academy of Child and Adolescent Psychiatry |d 1992 |g 59(2020), 10 vom: 01. Okt., Seite 1107-1124 |w (DE-627)NLM012953202 |x 1527-5418 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2020 |g number:10 |g day:01 |g month:10 |g pages:1107-1124 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaac.2020.05.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2020 |e 10 |b 01 |c 10 |h 1107-1124 | ||